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ABSTRACT
Objective: To assess the cost-effectiveness of group cognitive behavior
therapy (gCBT) in comparison with routine primary care for women with
postnatal depression in the UK.
Methods: Our analysis was based on a systematic literature review of
the relative clinical effectiveness of gCBT compared with routine pri-
mary care and further reviews, supplemented with expert opinion of the
likely cost of providing gCBT and the duration of comparative advan-
tage for gCBT. Raw data were used to estimate a statistical relationship
between changes in the Edinburgh Postnatal Depression Score (EPDS)
values and changes in short-form six dimensions’ (SF-6D) values. A
mathematical model was constructed, and probabilistic sensitivity analy-
ses were undertaken to estimate the mean cost per quality-adjusted life-
year (QALY) and to evaluate the expected value of perfect information
(EVPI).
Results: The mean cost per QALY from the stochastic analysis was esti-
mated to be £36,062; however, there was considerable uncertainty around
this value. The EVPI was estimated to be greater than £64 million; the key
uncertainties were in the cost per woman of providing treatment and in the
statistical relationship between changes in EPDS values and changes in
SF-6D values. The expected value of perfect partial information for both
of these parameters was in excess of £25 million.
Conclusions: Given the current information, the use of gCBT does not
appear to be cost-effective; however, this decision is uncertain. The value
of information analyses conducted indicates that further research to
provide robust information on key parameters is needed and appears
justiﬁed in cost-effective terms.
Keywords: cognitive behavior therapy, mathematical modeling, postnatal
depression, value of information.
Introduction
The term “postnatal depression” (PND) has been used to
describe a wide range of distressing symptoms after childbirth.
This has led some clinicians to describe women as suffering from
PND on the basis of the symptom of lowered or depressed mood
[1]. It is more common, however, for a clinical diagnosis to be
made based on the pattern and severity of symptoms. PND is also
referred to as puerperal depression, postpartum depression, and
perinatal depression, and is deﬁned as a nonpsychotic depressive
episode meeting standardized diagnostic criteria for a minor or
major depressive disorder, beginning in or extending into the
postnatal period, which is usually deﬁned at up to 12 months
postpartum [2].
Current criteria for the measurement of depression are pro-
vided in two major international classiﬁcations (International
Classiﬁcation of Diseases-10 [3] and Diagnostic and Statistical
Manual of Mental Disorders-IV [4]). In addition to, or as an
alternative to, these diagnostic criteria, self-report scales such as
the Edinburgh Postnatal Depression Scale (EPDS) are used to
identify PND and are widely used [5]. The EPDS scale consists of
10 Likert-format items relating to depression symptomology and
has also been shown to measure anxiety symptomology [6].
Items are scored on a 0–3 scale and provide a range for the total
score of between 0 and 30. Total scores within the range 12–30
suggest signiﬁcant depression [7]. The EPDS has been shown to
have reasonably good validity with a sensitivity of 86% and a
speciﬁcity of 78% in detecting women with research diagnostic
criteria for depression [6].
There is substantial evidence to support the use of cognitive
behavioral therapy (CBT) at an individual level for the treatment
of depression [8], and psychological treatments are recom-
mended by the National Institute for Health and Clinical Excel-
lence (NICE) for PND [9]. Nevertheless, access is limited due to
expense, waiting lists, and availability of therapists. Group CBT
(gCBT) may offer a solution by reducing the contact time
between therapists and increasing the number of available places
for treatment. In 2003, there was an estimated number of
695,500 births per annum [10]; assuming that 17.3% of women
have an EPDS score of 12 or over [11], this would equate to an
estimated 120,000 women suffering from PND per annum. With
costs of individual CBT estimated to be £1700 [12], the costs of
treating all women suspected of having PND would be in the
region of £200 million. Our objective was to assess the cost-
effectiveness of providing gCBT rather than routine primary care
(RPC) for women with PND in the UK in line with the NICE
reference case [13]. As such, a National Health Service and
personal social services approach was used.
Methods
A group of clinical advisors were convened to provide guidance
and consisted of professors of psychology, applied psychological
therapies, primary medical care, clinical psychology, and psycho-
logical medicine, and a consultant cognitive behavioral psycho-
therapist, psychiatrist, and a service user.
A systematic review of the clinical efﬁcacy of gCBT was
undertaken and is reported in detail elsewhere [12]. Only one
study [14], a randomized controlled trial (RCT), was deemed
applicable to the decision problem. This small RCT (n = 45) was
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UK based, had a clear CBT component in the psycho-educational
treatment intervention arm, and reported data on EPDS at base-
line, end of treatment (8 weeks), and at a 6-month follow-up.
Women, who were suspected of having PND based on the EPDS,
attended one session per week for 8 weeks, which was of 2-hour
duration and was held in groups of four to six women. The
comparative gain (i.e., reduction) in EPDS values for gCBT com-
pared with RPC was 3.48 (95% CI 0.23–6.73) at the end of
treatment period (8 weeks) and 4.48 (95% CI 1.01–7.95) at
6-month follow-up. Based on clinical advice, it was assumed in
the base-case that the comparative gain in EPDS of gCBT com-
pared with RPC would rise linearly to a peak value at 8 weeks,
stay constant until 6 months, and then decline linearly to zero 12
months after randomization (Fig. 1). The duration of compara-
tive advantage was assumed to be 12 months as this was when
symptoms of depression were no longer assumed to be postnatal
in origin [2]. Sensitivity analyses were used to assess the robust-
ness of the results in relation to changes in the duration of
comparative advantage. To estimate the effect of gCBT during
the period of 8 weeks to 6 months, the two data sets from the
relevant RCT [14] were pooled; the beneﬁts associated with the
reduction in the conﬁdence intervals were assumed to outweigh
the loss of any (unreported) correlation between the separate
time points. The pooled comparative advantage in EPDS was
estimated to be 3.98 (95% CI 3.27–4.69).
In order that the effectiveness could be measured in terms of
quality-adjusted life-years (QALYs), a mapping from EPDS to a
utility score was required. Raw data were obtained from the
authors of the PoNDER trial [11], which consisted of paired
values for both EPDS and the short-form six dimensions (SF-6D),
a utility measure [15]. Data were analyzed from 401 women with
an EPDS score of 12 or greater at 6 weeks after childbirth, which
had completed both the EPDS and the SF-6D questionnaire at
both 6 weeks and 6 months. Figure 2 provides a plot of the
change in EPDS value against change in SF-6D value. A moderate
relationship was observed (R2 = 0.27) that indicated that as the
EPDS score improved (i.e., became lower), the SF-6D score
improved (i.e., became higher). It is also noted that, regardless of
any change in EPDS score, the utility of a woman was 0.0625
higher at 6 months compared with 6 weeks. This is most likely to
be explained by the fact that the women would be expected to
achieve more hours of sleep at 6 months than at 6 weeks, which
would be accounted for in the SF-6D but not within the EPDS as
it does not include a sleep component. A plot of residuals (not
provided) showed no marked bias in the regression ﬁt. Tests for
heteroskedasticity indicated that the variance was not constant
(P = 0.008), and thus, for probabilistic sensitivity analyses (PSA),
robust errors were sampled from the regression. The QALYs
obtained through gCBT treatment could thus be estimated by
transforming the gain in EPDS into utility values and then mul-
tiplying each gain by the appropriate time period.
The costs of providing gCBT were estimated from the
resources reported in the RCT [14] (£1317) and from an assess-
ment made by a group of experts regarding the likely resources
required (£1246); derivation of these values are provided in
detail elsewhere [12]. With associated sundry costs that may be
expected, a cost of £1500 per woman treated was assumed in the
base-case.
The cost-effectiveness of gCBT compared with RPC was esti-
mated under a number of scenarios. These were a base-case
analysis using ﬁxed values for cost per woman of providing
treatment and for the duration of comparative efﬁcacy, but sto-
chastic values for assumed efﬁcacy and the transformation into
SF-6D values; a series of sensitivity analyses showing the impact
of changing variables; and a full PSA using 1000 parameter
conﬁgurations. For the PSA evaluation, distributions were ﬁtted
to those uncertain variables where data were not robust. A
triangular distribution was assumed for the cost per woman of
providing treatment with a minimum of £750, a maximum of
£2000, and a mode of £1500. This distribution allowed the cost
to reduce were economies of scale to be achieved with wide-
spread use, but to increase were fewer women willing to partici-
pate per class. A triangular distribution was also used for the
comparative advantage of gCBT compared with RPC. A
minimum duration of 1 year was assumed with a maximum of 2
years and a mode of 1 year, which incorporated the possibility
that the beneﬁcial effects of gCBT may persist beyond 12 months.
These distributions were not viewed as unreasonable by our
clinical experts. The mean values were a cost per woman of
£1418 and duration of comparative advantage of 16 months,
whereas these values differed from the deterministic, most likely,
values (£1500 and 12 months, respectively). Nevertheless, the
clinicians did not feel uncomfortable with this discrepancy as the
distributions were likely to be skewed. It is acknowledged that
the results from the PSA would be more favorable to gCBT
treatment than the deterministic result but that the PSA answers
provided a more realistic assessment of the cost-effectiveness of
the intervention.
Cholesky decomposition techniques [16] were used to ensure
that the slope and constant within the transformation of changes
in the EPDS values to changes in SF-6D values were consistent
with the raw data. Due to the small time horizon of the model,
neither beneﬁts nor costs were discounted.
The PSA facilitated expected value of information analyses,
which estimated the expected value of perfect information (EVPI)
4.5
4
3.5
3
2.5
2
1.5
1
0.5
0
0 4 8 12 16 20
Time since randomization (weeks)
C
o
m
p
ar
at
iv
e 
ad
va
n
ta
g
e 
in
E
P
D
S
 a
ss
o
ci
at
ed
 w
it
h
 g
C
B
T
24 28 32 36 40 44 48 52 56
Figure 1 The conceptual model regarding the efﬁcacy of group cognitive
behavior therapy (gCBT) compared with routine primary care (RPC).
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Figure 2 A regression of change in short-form six dimensions (SF-6D) against
change in Edinburgh Postnatal Depression Score (EPDS).
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[17] and the expected value of perfect partial information
(EVPPI) [18]. EVPI provides the maximum expenditure a
decision-maker would pay to remove all uncertainty in the deci-
sion problem; EVPPI provides the maximum expenditure if all
uncertainty was removed in one, or a subset, of parameters. In
our analysis, we calculate the EVPPI for the assumed advantage
of gCBT compared with RPC in terms of EPDS, the cost of gCBT
per woman treated, the duration of comparative advantage of
gCBT, and the statistical relationship between EPDS and the
SF-6D. For the value of information analyses, it was deemed that
of the two thresholds reported by NICE [13], a threshold of
£30,000 per QALY was more appropriate than a threshold of
£20,000 as potential QALY impacts on the child that have been
previously reported [19–21] were not incorporated within the
model because of the lack of appropriate data, and therefore,
there were “strong reasons to indicate that the assessment of the
change in HRQL has been inadequately captured, and may there-
fore misrepresent the health utility gained” [13].
Results
In the base-case scenario, 0.032 QALYs were provided at a cost
of £1500, resulting in a cost per QALY of £46,462. The results
from the series of sensitivity analyses are provided in Table 1. It
is seen that the cost per QALY is labile and that there will be
plausible scenarios that have a cost per QALY ratio below
£30,000 and also below £20,000, the lower of the two com-
monly reported thresholds for cost-effectiveness [13].
The results obtained from the base-case and the full PSA
cannot be directly compared because of the means of the cost per
woman treated and the comparative advantage being different to
those in the deterministic base-case. The PSA incorporating sto-
chastic values for costs estimated that an additional 0.039
QALYs would be provided at a cost of £1418, resulting in a cost
per QALY of £36,062. The cost-effectiveness acceptability curve
is shown in Figure 3.
The EVPI value was estimated to be £53.50 per woman
receiving gCBT. As previously detailed, an estimated 120,000
women have PND per annum. If it was hypothesized that gCBT
may be the most appropriate treatment for the forthcoming 10
years, then this would equate to 1,200,000 women who would
be estimated to beneﬁt from increased knowledge regarding the
efﬁcacy, cost, and duration of comparative advantage of gCBT
compared with RPC. Combining the number of women who
could beneﬁt with the EVPI per woman indicates that decision-
makers would be willing to pay a maximum of £64 million to
remove all uncertainty in the decision problem. This amount
appears more than sufﬁcient to adequately fund additional
research to assess the value of the uncertain parameters.
The EVPPI analyses showed that two parameters contributed
considerably to the uncertainty in whether gCBT was cost-
effective compared with RPC (Fig. 4). These were the cost of
providing gCBT per woman treated and the relationship between
EPDS values and SF-6D values. Nevertheless, even those vari-
ables with a lesser impact would still have EVPPI values in excess
of £500,000 when the number of women likely to beneﬁt from
the greater knowledge is considered.
Discussion
The current work provides the ﬁrst published estimate of the
cost-effectiveness of gCBT for PND in the UK. The base-case cost
per QALY (£46,462) and the value from the full PSA (£36,062)
are relatively high compared with currently used thresholds [13].
Table 1 The results from the series of sensitivity analyses
Sensitivity analysis
Mean cost per
woman (£)
Mean QALY
gain per woman
Mean cost
per QALY (£)
Base-case 1,500 0.032 46,462
Cost per woman decreased to £750 750 0.032 23,231
Cost per woman increased to £2,000 2,000 0.032 61,948
Lower 95% of efﬁcacy assumed (EPDS decrease of 3.27) 1,500 0.027 56,626
Upper 95% of efﬁcacy assumed (EPDS decrease of 4.69) 1,500 0.038 39,481
Linear decline in advantage extended to 18 months 1,500 0.044 34,382
Cost per woman decreased to £1000, EPDS decrease of 4.3 assumed, linear
decline in advantage extended to 18 months
1,000 0.047 19,230
EPDS, Edinburgh Postnatal Depression Score; QALY, quality-adjusted life-year.
Figure 3 The cost-effectiveness acceptability curve for group cognitive
behavior therapy compared with routine primary care having ﬁtted statistical
distributions to uncertain parameters. QALY, quality-adjusted life-year.
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Nevertheless, there is considerable uncertainty in the model
parameters. EVPI analyses indicate that the potential gain in
ensuring the correct decision could be valued as high as £64
million, which would sufﬁciently cover the costs of undertaking
further research to obtain more robust data even if there is
inaccuracy in some of the ﬁtted distributions.
Limitations within our work include the fact that no data were
available comparing gCBT with CBT provided on an individual
basis, which should be included as an appropriate comparator. It
is strongly recommended that any future RCTs incorporating
gCBT should also include an arm assessing the efﬁcacy of indi-
vidual CBT.Additionally, the implications in terms of effectiveness
and cost of women wishing to move from individual to group
treatment and vice versa should be assessed. The level of con-
founding within the main RCT used in our analyses due to the
level of concurrent medication was also unknown; antidepressant
use was included as a covariate within the analyses, but it is
unclear whether themedicationwas identical. Any future research
should explicitly control for concurrent medication.
Only one RCT was used to populate the efﬁcacy data for
gCBT. Given that both the number of participants and the
number of clinicians involved were small, there is a possibility
that the results are strongly inﬂuenced by the therapist. Addition-
ally, as studies from countries outside the UK were not consid-
ered appropriate because of marked differences in the number of
participants per class [22], it is unclear whether our results are
generalizable to other countries.
The lack of perfect sensitivity and speciﬁcity of the EPDS in
identifying women with PND will mean that some women are
incorrectly diagnosed. Nevertheless, this is unlikely to alter our
conclusions as the estimated gain in utility was calculated from a
study collecting paired data for EPDS and SF-6D, which would
incorporate some women with an EPDS of 12 or greater that did
not have PND. Additional analyses were undertaken assuming a
cut point of 8 on the EPDS as this threshold is reported to
increase the sensitivity to over 90% [6]. Analysis of the 942
women in the PoNDER data set with an EPDS score of 8 or
greater resulted in the same relationship between changes in
EPDS and changes in SF-6D as that observed in women with an
EPDS score of 12 or more (n = 401), namely, that each point
decrease in EPDS was associated with a increase of 0.0113 in the
SF-6D. Thus, the cost-effectiveness when offering treatment to
women with an EPDS score of 8 or more is likely to be similar to
that for treating women with an EPDS score of 12 or more.
Nevertheless, due to the larger numbers involved, the value of
information, which is already large, would approximately double
(a multiplication factor of 942/401) if it were women with an
EPDS of 8 or greater offered treatment.
It is recommended that any future RCT should be larger in
size, incorporate an individual CBT arm, explicitly control for
concurrent medication, and attempt to evaluate the quality of life
for women at 1-year post-randomization preferably directly with
a utility measure such as the SF-6D to obviate the need for
transforming between scales.
There is also considerable uncertainty in the costs of treating
women with gCBT, which may beneﬁt from economies of scale.
It is therefore recommended that any future research explicitly
calculate the cost per woman of gCBT, preferably from the later
period of a large trial in order that any setup costs do not unduly
bias this value.
Conclusion
Our exploratory analyses indicate that based on current data,
gCBT is unlikely to be more cost-effective than RPC; however,
there is considerable uncertainty in the decision which is prima-
rily due to lack of robust data on the costs of providing gCBT
and on the relationship between changes in EPDS values and
changes in SF-6D values. Research to reduce the uncertainty in
these parameters is needed to ascertain if gCBT is a cost-effective
intervention. The value of information analyses conducted indi-
cates that the beneﬁts associated with prospective data collection
more than cover the costs of the further research recommended.
We acknowledge Jane Morrell and the PoNDER team for per-
mission to use the data that allowed a relationship between
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the National Institute for Health Research Health Technology
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and opinions expressed therein are those of the authors and do
not necessarily reﬂect those of the Department of Health.
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